Osimertinib

Red

Brand Name(s):TAGRISSO

Indication:Treatment of early stage non-small-cell lung cancer.

Positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults. (EGFR) T790M mutation.

Untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

Rationale:1,2,8

Considered:Feb-16

Review Date:Jun-26

Comments:
License extention has been extended via the MHRA (Project Orbis) to include treatment of early stage non-small-cell lung cancer.

Osimertinib is recommended as an option for epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults, only if their disease has progressed after first-line EGFR tyrosine kinase inhibitor. NICE TA653.

Osimertinib is recommended as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults. NICE TA654